检索范围:
排序: 展示方式:
Hydroxyl radical-involved cancer therapy via Fenton reactions
《化学科学与工程前沿(英文)》 2022年 第16卷 第3期 页码 345-363 doi: 10.1007/s11705-021-2077-3
关键词: hydroxyl radical Fenton catalyst hydrogen peroxide cancer therapy
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
《医学前沿(英文)》 2021年 第15卷 第2期 页码 221-231 doi: 10.1007/s11684-020-0812-7
关键词: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Progress and challenges in RET-targeted cancer therapy
《医学前沿(英文)》 2023年 第17卷 第2期 页码 207-219 doi: 10.1007/s11684-023-0985-y
关键词: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug resistance
Bioorthogonal chemistry based on-demand drug delivery system in cancer therapy
《化学科学与工程前沿(英文)》 2023年 第17卷 第4期 页码 483-489 doi: 10.1007/s11705-022-2227-2
关键词: bioorthogonal reaction cancer therapy metabolic glycoengineering bioorthogonal catalytic patch
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
Particle therapy for cancers: a new weapon in radiation therapy
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 165-172 doi: 10.1007/s11684-012-0196-4
Particle irradiation started to draw attention in the past decade and has now become a hotspot in the radiation oncology community. This article reviews the most advanced developments in particle irradiation, focusing on the characteristics of proton and carbon ions in radiation physics and radiobiology. The Bragg peak of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancer irradiation because the Bragg peak permits the accurate concentration of the dose on the tumor, thus sparing the adjacent normal tissues. Moreover, carbon ion has more radiobiological benefits than photon and proton beams. These benefits include stronger sterilization effects on intrinsic radio-resistant tumors and more effective killing of hypoxic, G0, and S phase cells. Compared with the most advanced radiation techniques using photon, such as three-dimensional conformal radiation therapy and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in local control and survival for head and neck cancers, prostate carcinoma, and pediatric cancers. Carbon therapy in Japan showed even more promising results than proton therapy. The local controls and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancer, hepatocellular carcinoma, prostate carcinoma, and head and neck cancers, especially for such highly resistant tumors as melanoma. The non-invasive nature of particle therapy affords more patients with chances to receive and benefit from treatment. Particle therapy is gradually getting attention from the oncology community. However, the cost of particle therapy facilities has limited the worldwide use of this technology.
关键词: radiation therapy particle therapy proton carbon cancer
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
Iron oxide nanoparticle-based theranostics for cancer imaging and therapy
Xiaoqing REN,Hongwei CHEN,Victor YANG,Duxin SUN
《化学科学与工程前沿(英文)》 2014年 第8卷 第3期 页码 253-264 doi: 10.1007/s11705-014-1425-y
关键词: theranostics iron oxide nanoparticles MRI drug delivery photothermal therapy photodynamic therapy
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
《医学前沿(英文)》 2022年 第16卷 第5期 页码 766-772 doi: 10.1007/s11684-021-0916-8
关键词: anlotinib chemotherapy short-term relapsed small-cell lung cancer
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
《医学前沿(英文)》 2023年 第17卷 第6期 页码 1135-1169 doi: 10.1007/s11684-023-1050-6
关键词: pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy resistance
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
Emerging immunological strategies: recent advances and future directions
《医学前沿(英文)》 2021年 第15卷 第6期 页码 805-828 doi: 10.1007/s11684-021-0886-x
关键词: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer vaccines
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
《医学前沿(英文)》 2022年 第16卷 第3期 页码 307-321 doi: 10.1007/s11684-022-0927-0
关键词: tumor immunotherapy immune checkpoint inhibitor antibiotics gut microbiota drug–drug interaction
标题 作者 时间 类型 操作
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
期刊论文
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
Iron oxide nanoparticle-based theranostics for cancer imaging and therapy
Xiaoqing REN,Hongwei CHEN,Victor YANG,Duxin SUN
期刊论文
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
期刊论文
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic
期刊论文